Ceruloplasmin is a better predictor of the long-term prognosis compared with fibrinogen, CRP, and IL-6 in patients with severe unstable angina

Angiology

Volumn 60, Issue 1, 2009, Pages 50-59

  Ziakas, Antonios ^a,b   Gavrilidis, Stavros ^a   Souliou, Efthimia ^a   Giannoglou, George ^a   Stiliadis, Ioannis ^a   Karvounis, Haralambos ^a   Efthimiadis, George ^a   Mochlas, Sotirios ^a   Vayona, M Arvanitidou ^a   Hatzitolios, Apostolos ^a   Savopoulos, Christos ^a   Pidonia, Ifigenia ^a   Parharidis, George ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

C reactive protein; Ceruloplasmin; Fibrinogen; Interleukin 6; Prognosis; Severe unstable angina

Indexed keywords

C REACTIVE PROTEIN; CERULOPLASMIN; FIBRINOGEN; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MALE; PROGNOSIS; PROTEIN BLOOD LEVEL; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; AGED, 80 AND OVER; ANGINA, UNSTABLE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CERULOPLASMIN; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TROPONIN T; UP-REGULATION;

EID: 59149091190     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319708314249     Document Type: Article

References (66)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999 ; 340: 115-126.
2. Van Snick J. Interleukin 6 an overview. Annu Rev Immunol. 1990 ; 8: 253-278.
3. Danesh J., Collins R., Appleby P., Peto R. Association of fibrinogen, C-reactive protein, albumin or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998 ; 279: 1477-1482.
4. Toss H., Lindahl B., Siegbahn A., Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation. 1997 ; 96: 4204-4210.
5. Becker R., Cannon C., Bovill E., et al. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q wave myocardial infarction. Am J Cardiol. 1996 ; 78: 142-147.
6. Liuzzo G., Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994 ; 331: 417-424.
7. Lindahl B., Toss H., Siegbahn A., Venge P., Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Framing during instability in coronary artery disease. N Engl J Med. 2000 ; 343: 1139-1147.
8. Ferreiros ER, Boissonnet CP, Pizarro R., et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation. 1999 ; 100: 1958-1963.
9. Lindmark E., Diderholm E., Wallentin L., Siegbahn A. Relationship between interleukin-6 and mortality in patients with unstable coronary artery disease. JAMA. 2001 ; 286: 2107-2113.
10. Biasucci LM, Vitelli A., Liuzzo G., et al. Elevated levels of interleukin-6 in unstable angina. Circulation. 1996 ; 94: 874-877.
11. Biasucci LM, Vitelli A., Liuzzo G., et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 1999 ; 99: 2079-2084.
12. Calvin JE, Klein LW, VandenBerg BJ, et al. Risk stratification in unstable angina. Prospective validation of the Braunwald classification. JAMA. 1995 ; 273: 136-141.
13. Holmvang L., Luscher M., Clemmensen P., Thygesen K., Grande P. Very early risk stratification using combined ECG and biochemical assessment in patients with unstable coronary artery disease (a thrombin inhibition in myocardial ischemia [TRIM] substudy). Circulation. 1998 ; 98: 2004-2009.
14. Seres L., Valle V., Marrugat J., et al. Usefulness of hospital admission risk stratification for predicting nonfatal acute myocardial infarction or death six months later in unstable angina pectoris. Am J Cardiol. 1999 ; 84: 963-969.
15. Osler A., Whooley MA, Oler J., Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA. 1996 ; 276: 811-815.
16. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 1996 ; 347: 561-568.
17. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb-IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998 ; 338: 1488-1497.
18. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998 ; 339: 436-443.
19. The TIMI IIIb Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIb trial. Circulation. 1994 ; 89: 1545-1556.
20. Boden W., O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med. 1998 ; 338: 1785-1792.
21. Fox PL, Mazumder B., Ehrenwald E., Mukhopadhyay CK Caeruloplasmin and cardiovascular disease. Free Radic Biol Med. 2000 ; 28: 1735-1744.
22. Fox PL, Mukhopadhyay C., Ehrenwald E. Structure, oxidant activity, and cardiovascular mechanisms of human caeruloplasmin. Life Sci. 1995 ; 56: 1749-1758.
23. Floris G., Medda R., Padiglia A., Musci G. The physiopathological significance of caeruloplasmin. Biochem Pharmacol. 2000 ; 60: 1735-1741.
24. Harris ED A requirement for copper in angiogenesis. Nutr Rev. 2004 ; 62: 60-64.
25. Hannan GN, McAuslen BR Modulation of synthesis of specific proteins in endothelial cells by copper, cadmium, and disulfiram: an early response to an angiogenic inducer of cell migration. J Cell Physiol. 1982 ; 111: 207-212.
26. Shukla N., Maher J., Masters J., Angelini GD, Jeremy JY Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor. Atherosclerosis. 2006 ; 187: 238-250.
27. Bustamante JB, Mateo MC, Fernandez J., de Quiros B., Manchado OO Zinc, copper and ceruloplasmin in arteriosclerosis. Biomedicine. 1976 ; 25: 244-245.
28. Powell JT, Muller BR, Greenhalgh RM Acute phase proteins in patients with abdominal aortic aneurysms. J Cardiovasc Surg. 1987 ; 28: 528-530.
29. Jayakumari N., Ambikakumari V., Balakrishnan KG, Iyer KS Antioxidant status in relation to free radical production during stable and unstable anginal syndromes. Atherosclerosis. 1992 ; 94: 183-190.
30. Belch JJ, Chopra M., Hutchison S., et al. Free radical pathology in chronic arterial disease. Free Radic Biol Med. 1989 ; 6: 375-378.
31. Braunwald E. Unstable angina: a classification. Circulation. 1989 ; 80: 410-414.
32. Kakafika AI, Liberopoulos EN, Mikhailidis DP Fibrinogen: a predictor of vascular disease. Curr Pharm Des. 2007 ; 13: 1647-1659.
33. Ferri C., Croce G., Cofini V., et al. C-reactive protein: interaction with the vascular endothelium and possible role in human atherosclerosis. Curr Pharm Des. 2007 ; 13: 1631-1645.
34. Dubinski A., Zdrojewicz Z. The role of interleukin-6 in development and progression of atherosclerosis. Pol Merkur Lekarski. 2007 ; 22: 291-294.
35. Liuzzo G., Buffon A., Biasucci LM, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation. 1998 ; 98: 2370-2376.
36. Hoffmeister H., Jur M., Wendel HP, Heller W., Seipel L. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation. 1995 ; 91: 2520-2527.
37. Fuchs J., Pinhas A., Davidson E., Rottenber Z., Agmon J., Weinberger I. Plasma viscosity, fibrinogen, and hematocrit in the course of unstable angina. Eur Heart J. 1990 ; 11: 1029-1032.
38. Jayakumari N., Ambikakumari V., Balakrishnan KG, Iyer KS Antioxidant status in relation to free radical production during stable and unstable anginal syndromes. Atherosclerosis. 1992 ; 94: 183-190.
39. Klebanoff SJ Bactericidal effect of Fe2+, ceruloplasmin, and phosphate. Arch Biochem Biophys. 1992 ; 295: 302-308.
40. Sigal LH, Ron Y. The acute phase response to inflammation. Immunology and inflammation. Basic mechanisms and clinical consequences. International Editions. 1994 ; 16: 287-301.
41. Kushner I., Broder ML, Karp D. Control of the acute phase response: serum C-reactive protein kinetics after acute myocardial infarction. J Clin Invest. 1978 ; 61: 235-242.
42. Liuzzo G., Biasucci LM, Rebuzzi AG, et al. Plasma protein acute phase response in unstable angina is not induced by ischemic injury. Circulation. 1996 ; 94: 2374-2380.
43. Biasucci LM, Liuzzo G., Caligiuri G., et al. Episodic activation of the coagulation system in unstable angina does not elicit an acute phase reaction. Am J Cardiol. 1996 ; 77: 85-87.
44. Rallidis LS, Zolindaki MG, Manioudaki HS, Laoutaris NP, Velissaridou AH, Papasteriadis EG Prognostic value of C-reactive protein, fibrinogen, interleukin-6, and macrophage colony stimulating factor in severe unstable angina. Clin Cardiol. 2002 ; 25: 505-510.
45. Sanchis J., Bodi V., Navarro A., et al. Prognostic factors in unstable angina with dynamic electrocardiographic changes. Value of fibrinogen. Rev Esp Cardiol. 2002 ; 55: 921-927.
46. Morrow DA, Rifai N., Antman EM, et al. C-reactive protein is a potent predictor of mortality independently or in combination with troponin T in acute coronary syndromes: A TIMI 11a substudy. J Am Coll Cardiol. 1998 ; 31: 1460-1465.
47. Koukkunen H., Penttila K., Kemppainen A., et al. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann Med. 2001 ; 33: 37-47.
48. Ford ES Serum copper concentration and coronary heart disease among US adults. Am J Epidemiol. 2000 ; 151: 1182-1188.
49. Jeremy JY, Shukla N., Muzaffar S., HandleyA, Angelini GD Reactive oxygen species, vascular disease and cardiovascular surgery. Curr Vasc Pharmacol. 2004 ; 2: 229-236.
50. Tapiero H., Townsend DM, Tew KD Trace elements in human physiology and pathology. Copper Biomed Pharmacother. 2003 ; 57: 386-398.
51. Daimon M., Susa S., Yamatani K., et al. Hyperglycaemia is a factor for an increase in serum caeruloplasmin in type 2 diabetes. Diab Care. 1998 ; 21: 1525-1528.
52. Walter RM Jr, Uriu-Hare JY, Olin KL, et al. Copper, zinc, manganese and magnesium status and complications of diabetes mellitus. Diab Care. 1991 ; 14: 1050-1056.
53. Zargar AH, Shah NA, Masoodi SR, et al. Copper, zinc and magnesium levels in non-insulin dependent diabetes mellitus. Postgrad Med. 1998 ; J74: 665-668.
54. Kim CH, Park JY, Kim JY, et al. Elevated serum ceruloplasmin levels in subjects with metabolic syndrome: a population-based study. Metabolism. 2002 ; 51: 838-842.
55. Dudman NP, Wilcken DE Increased plasma copper in patients with homocystinuria due to cystathionine β-synthase deficiency. Clin Chim Acta. 1983 ; 127: 105-113.
56. Engstrom G., Janzon L., Berglund G., et al. Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive proteins. Arterioscler Thromb Vasc Biol. 2002 ; 22: 2054-2058.
57. Engstrom G., Stavenow L., Hedblad B., et al. Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke. Diabetes. 2003 ; 52: 442-447.
58. Engstrom G., Hedblad B., Stavenow L., et al. Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes. 2003 ; 52: 2097-2101.
59. Lind P., Hedblad B., Stavenow L., Janzon L., Eriksson KF, Lindgarde F. Influence of plasma fibrinogen levels on the incidence of myocardial infarction and death is modified by other inflammation-sensitive proteins: a long-term cohort study. Arterioscler Thromb Vasc Biol. 2001 ; 21: 452-458.
60. Klipstein-Grobusch K., Grobbee DE, Koster JF, et al. Serum caeruloplasmin as a coronary risk factor in the elderly: the Rotterdam study. Br J Nutr. 1999 ; 81: 139-144.
61. Ehrenwald E., Chisolm GM, Fox PL Intact human caeruloplasmin oxidatively modifies low density lipoprotein. J Clin Invest. 1994 ; 93: 1493-1501.
62. Mukhopadhyay CK, Fox PL Ceruloplasmin copper induces oxidant damage by a redox process utilizing cell-derived superoxide as a reductant. Biochemistry. 1998 ; 37: 14222-14229.
63. Mukhopadhyay CK, Ehrenwald E., Fox PL Ceruloplasmin enhances smooth muscle cell and endothelial cell mediated low density lipoprotein oxidation by a superoxide dependent mechanism. J Biol Chem. 1996 ; 271: 1473-1478.
64. Salonen JT, Salonen R., Seppanen K., Kantola M., Suntioinen S., Korpela H. Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis. Br Med J. 1991 ; 302: 756-760.
65. Mezzetti A., Guglielmi MD, Pierdomenico SD, et al. Increased systemic oxidative stress after elective endarterectomy: relation to vascular healing and remodeling. Arterioscler Thromb Vasc Biol. 1999 ; 19: 2659-2665.
66. Mänttäri M., Manninen V., Huttunen JK, et al. Serum ferritin and ceruloplasmin as coronary risk factors. Eur Heart. 1994 ; J15: 1599-1603.